---
title: Medical Device Regulation in India (CDSCO): A Growing Market
description: India CDSCO medical device regulation for EU startups: A-D classification, Authorized Indian Agent, registration certificates, and realistic timelines.
authors: Tibor Zechmeister, Felix Lenhard
category: FDA & International Market Access
primary_keyword: India CDSCO medical device
canonical_url: https://zechmeister-solutions.com/en/blog/india-cdsco-medical-device
source: zechmeister-solutions.com
license: All rights reserved. Content may be cited with attribution and a link to the canonical URL.
---

# Medical Device Regulation in India (CDSCO): A Growing Market

*By Tibor Zechmeister (EU MDR Expert, Notified Body Lead Auditor) and Felix Lenhard.*

> **The India CDSCO medical device framework operates under the Medical Devices Rules, 2017 (often called MDR-IN — not to be confused with EU MDR). CDSCO classifies devices into four risk classes (A, B, C, D), requires a locally resident Authorized Indian Agent, and issues registration certificates through its online SUGAM portal. Timelines for foreign manufacturers typically run 6–12 months for lower-risk devices and longer for higher-risk categories.**

**By Tibor Zechmeister and Felix Lenhard.**

**A note on terminology.** Throughout this post, *MDR* without qualification means the **EU Medical Device Regulation (EU) 2017/745**. When we refer to Indian regulations, we use *MDR-IN* or *Medical Devices Rules, 2017* explicitly. Do not conflate the two — the frameworks, terminology, and obligations are distinct.

## TL;DR
- India regulates medical devices through the Central Drugs Standard Control Organization (CDSCO) under the Medical Devices Rules, 2017 (MDR-IN) .
- Classification is A, B, C, D — broadly aligned with GHTF/IMDRF, where A is lowest risk and D highest.
- Foreign manufacturers must appoint an Authorized Indian Agent (AIA) who holds the import licence and registration certificate.
- Applications are filed via the CDSCO SUGAM online portal; the deliverable is a Registration Certificate and, for imports, an Import Licence (Form MD-15) .
- Language: English is accepted for most technical documentation, which is a major practical advantage over markets like Korea or China.
- Realistic timelines: Class A/B roughly 6–9 months; Class C/D roughly 9–18 months. India is large, growing, and — by Asian standards — relatively accessible.

## Why this matters

India is the fastest-growing major medical device market in the world. For EU startups, three things make it structurally attractive: English-language documentation is largely accepted, the Authorized Indian Agent model is well-understood, and the CDSCO SUGAM portal — while not perfect — is a real, functional online filing system.

But India is not a soft landing. The Medical Devices Rules, 2017, came into force in January 2018 and have been progressively expanding their scope ever since. Many device categories that were previously unregulated or notified-only are now under full registration. Classification judgments can be ambiguous, fees are non-trivial, and post-market obligations — once you are in — are real.

Tibor's experience with Indian registrations: the surprises are rarely the rules themselves. They are timeline drift, translation of *labeling* (not documentation) into regional languages for certain products, and AIA contracts that were signed in haste and regretted for years. Felix's Subtract to Ship principle applies with force: if your Indian go-to-market plan is "we will figure it out," you are not ready.

## What the Indian framework actually says

**Primary legislation.** The Drugs and Cosmetics Act, 1940, together with the Medical Devices Rules, 2017 (MDR-IN), and subsequent amendments form the backbone of Indian medical device regulation .

**Regulator.** The Central Drugs Standard Control Organization (CDSCO), under the Directorate General of Health Services, Ministry of Health and Family Welfare. The Drug Controller General of India (DCGI) heads CDSCO. State Licensing Authorities handle some lower-class activities domestically; imports and higher-class devices are centralized at CDSCO.

**Classification.** Four classes, risk-based:

- **Class A** — low risk (e.g., surgical dressings, many basic instruments).
- **Class B** — low-to-moderate risk (e.g., hypodermic needles, suction equipment).
- **Class C** — moderate-to-high risk (e.g., lung ventilators, bone fixation plates).
- **Class D** — high risk (e.g., heart valves, implantable defibrillators).

Classification follows risk-based rules set out in the First Schedule of MDR-IN. CDSCO publishes a growing list of classified devices. If your device is not on the list, you propose a classification with your application and CDSCO rules on it.

**Authorized Indian Agent (AIA).** Foreign manufacturers cannot apply directly. You must appoint an AIA — an Indian legal entity with a wholesale drug licence (Form 20B/21B or equivalent) . The AIA files the application on your behalf and is your legal interface with CDSCO. This is structurally similar to the EU Authorized Representative role under MDR Article 11, but the AIA typically also acts as the importer of record.

**Application route.** Imports of Class A and B devices, and imports of Class C and D devices, are filed through the CDSCO SUGAM online portal. The key deliverables are:

- **Import Licence (Form MD-15)** — authorizes import into India.
- **Registration Certificate** — previously a separate document, now largely integrated with the import licence under MDR-IN .

**Language.** English is accepted for technical documentation, DMF, and plant master file. Labeling carries additional rules, and specific product categories may need regional-language elements on consumer-facing labels.

**Clinical data.** For novel devices, Indian clinical investigations may be required. For devices already approved in reference regulatory jurisdictions (EU, US, Japan, Australia, Canada), CDSCO may accept foreign clinical data with a bridging rationale — this is a major time saver for well-documented CE-marked devices.

## A worked example

A Berlin-based startup has CE marking for a Class IIb infusion pump. They want to enter India because a large private hospital chain has placed a conditional pilot order.

- **Indian classification.** Under MDR-IN, the infusion pump maps to Class C.
- **AIA selection.** They spend 6 weeks interviewing three candidate AIAs. They choose one with existing CDSCO relationships in their device category, a Form 20B wholesale licence, and a clear contractual exit clause.
- **Documentation pack.** Their MDR technical file is the basis. They prepare the CDSCO dossier: Plant Master File, Device Master File, Essential Principles checklist, labeling samples, free sale certificate from their notified body country, ISO 13485 certificate, clinical evaluation summary.
- **Application.** Filed via SUGAM. First response from CDSCO arrives around 4 months later with 11 queries. They respond in 6 weeks. A second round of 3 queries. Import Licence (MD-15) issued around 11 months after initial submission.
- **Budget.** Roughly EUR 35,000–60,000 including AIA setup, government fees, translation of specific labeling elements, and regulatory consultant support. Ongoing AIA retainer: roughly EUR 1,500–3,000 per month depending on scope.

The timeline is realistic. The budget is honest. India is accessible — if you prepare.

## The Subtract to Ship playbook

1. **Confirm commercial pull before you file anything.** India is a big market, but "big" does not mean easy. If you do not have a named distributor, hospital, or group purchasing contact that will actually buy, you are filing on speculation. Subtract speculation.
2. **Select the AIA like you are hiring a co-founder.** The AIA holds your licence. A bad AIA relationship is the single most common cause of Indian market exits. Check references from other foreign manufacturers. Require written KPIs on query response time. Include a clean contractual transfer clause.
3. **Use your CE dossier as the backbone.** Your MDR technical documentation is 70–80 percent of what CDSCO needs. Do not rebuild it; restructure the relevant parts into the CDSCO format (Plant Master File, Device Master File).
4. **Confirm classification before you file.** Misclassification is the fastest way to burn six months. Either find your device on the CDSCO classified list or submit a classification opinion request before your main application.
5. **Budget for queries.** CDSCO queries are normal. Budget time (and AIA bandwidth) for two full query cycles. Plan your launch milestones with a 3-month buffer beyond the theoretical review window.
6. **Do not translate what you do not have to.** English is accepted for technical documentation. Pay for translation only where the rules explicitly require it — typically specific labeling elements. Over-translation is a classic startup money sink.
7. **Sequence India carefully.** India works well as a second or third international market after CE, not as your first non-EU step. Use FDA or a simpler APAC market first to build your international regulatory muscles.

## Reality Check

1. Do you have a written, recent CDSCO classification for your device — not just an MDR class and a guess?
2. Is your AIA contract signed, with clear exit rights and performance KPIs?
3. Is your Plant Master File and Device Master File prepared in CDSCO format, not just repurposed CE technical documentation with a new cover page?
4. Do you have a named Indian commercial partner that will actually buy once you are approved?
5. Have you budgeted for two rounds of CDSCO queries and a 12-month timeline, not an optimistic 6?
6. Does your QMS cover Indian post-market vigilance obligations including timelines and the AIA's role?
7. Is your labeling compliant with Indian rules, including any product-specific regional-language requirements?
8. If India disappeared from your roadmap tomorrow, would your startup still be viable?

If you cannot answer yes to at least six of these, slow down. The rupees you save by waiting six months are real.

## Frequently Asked Questions

**Is "Indian MDR" the same as EU MDR?**
No. In India, "MDR" informally refers to the Medical Devices Rules, 2017 (MDR-IN). EU MDR is Regulation (EU) 2017/745. The two frameworks are entirely separate. Always clarify which MDR you mean.

**Can my EU Authorized Representative act as my Authorized Indian Agent?**
No. The AIA must be an India-resident legal entity with an Indian wholesale drug licence. Your EU AR under MDR Article 11 has no role in India.

**How long does CDSCO approval take in practice?**
Class A/B: typically 6–9 months. Class C/D: typically 9–18 months. Timelines depend heavily on query quality, AIA responsiveness, and whether clinical data is required. Plan for the longer end.

**Do I need Indian clinical trials?**
Often not. For devices already approved in reference regulatory jurisdictions (EU, US, Japan, Canada, Australia), CDSCO frequently accepts foreign clinical data with a bridging rationale. For novel devices without such approvals, Indian clinical investigation may be required.

**What is the SUGAM portal?**
SUGAM is CDSCO's online filing system for drug and medical device applications. All medical device imports and registrations go through SUGAM. Your AIA operates the login and submits documents on your behalf.

**Do I need to translate my technical documentation into Hindi?**
No. English is accepted for technical documentation, DMF, and Plant Master File. Specific labeling rules may require certain information in regional languages for particular product categories — confirm this for your specific device.

## Related reading
- [International expansion sequencing](/blog/international-expansion-sequencing) — how to order CE, FDA, and APAC markets.
- [Prioritize international markets for medtech](/blog/prioritize-international-markets-medtech) — a framework for picking the next market.
- [Regulatory strategy for global market access](/blog/regulatory-strategy-global-market-access) — the strategic view above the country-by-country work.
- [IMDRF global harmonization for startups](/blog/imdrf-global-harmonization-startups) — where India aligns with global norms and where it diverges.
- [South Korea MFDS medical device regulation](/blog/south-korea-mfds-medical-device) — the neighbor APAC market that is often sequenced alongside India.

## Sources
1. Republic of India, Drugs and Cosmetics Act, 1940 and Medical Devices Rules, 2017 .
2. Central Drugs Standard Control Organization (CDSCO), SUGAM portal documentation and classification lists.
3. Regulation (EU) 2017/745, Article 11 (for AR/AIA comparison only).
4. EN ISO 13485:2016+A11:2021 — QMS, cited by CDSCO as accepted quality system evidence alongside Indian requirements.

---

*This post is part of the [FDA & International Market Access](https://zechmeister-solutions.com/en/blog/category/fda-international) cluster in the [Subtract to Ship: MDR Blog](https://zechmeister-solutions.com/en/blog). For EU MDR certification consulting, see [zechmeister-solutions.com](https://zechmeister-solutions.com).*